GLP-1 Receptor Agonist Market Overview and Key Insights: The GLP-1 Receptor Agonist market size reached USD 15.25 Billion in 2024 and is expected to register a revenue CAGR of 21.7% during the forecast period
S.GormanD
hypertension, type 2 DM, dyslipidemia) A meta-analysis of 22 trials involving over 17,000 patients determined that 50.2% and 17.5% of patients treated with GLP-1RAs (exenatide, semaglutide & liraglutide) experienced a weight loss of 5% and 10% compared to placebo, and that patients without type 2 diabetes achieved a significantly greater weight loss compared to those with diabetes (Vosoughi et al, 2022)
However, tirzepatide carries a higher incidence of gastrointestinal side effectsnausea, vomiting, and diarrheaparticularly during dose escalation, whereas Contrave's adverse events center on stimulation-related effects like insomnia and tremor
What happened: The 503B Bulks List proposal On April 30, 2026, the FDA announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List
( / and ApoE / mice on a Western diet (WD) were given daily injections of liraglutide or semaglutide or vehicle control for 12 to 17 weeks (12 to 14 weeks in ApoE / mice and 17 weeks in LDLr / mice)
